001052301 001__ 1052301
001052301 005__ 20260122203309.0
001052301 0247_ $$2doi$$a10.1111/joor.70039
001052301 0247_ $$2ISSN$$a0305-182X
001052301 0247_ $$2ISSN$$a1365-2842
001052301 0247_ $$2datacite_doi$$a10.34734/FZJ-2026-00916
001052301 037__ $$aFZJ-2026-00916
001052301 082__ $$a610
001052301 1001_ $$00000-0003-0792-0830$$aPrott, Lea S.$$b0$$eCorresponding author
001052301 245__ $$aTranscutaneous Auricular Vagus Nerve Stimulation for the Treatment of Myoarthropathic Symptoms Associated With Temporomandibular Disorders—A Pilot Randomised Controlled Trial
001052301 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
001052301 3367_ $$2DRIVER$$aarticle
001052301 3367_ $$2DataCite$$aOutput Types/Journal article
001052301 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769095107_2047
001052301 3367_ $$2BibTeX$$aARTICLE
001052301 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001052301 3367_ $$00$$2EndNote$$aJournal Article
001052301 520__ $$aABSTRACTBackground: Transcutaneous auricular vagus nerve stimulation (taVNS) is a safe and feasible treatment for a variety of acuteand chronic pain conditions. However, no evidence about taVNS effectiveness in patients with chronic pain associated with tem-poromandibular disorders (TMD) is available.Objective: To evaluate the feasibility of and compliance with taVNS in participants experiencing chronic TMD pain and poten-tial effects on pain, psychological well-being, muscle activity, and kinematics.Methods: Twenty adults with chronic TMD pain were randomised to receive taVNS (n = 10) or sham (n = 10). In the taVNSgroup, stimulation was performed on the left tragus for 4 h daily (25 Hz, pulse width 250 μs, 28 s on/32 s off). In the sham group,an inactive non-functional sham electrode was used. Patient-reported outcome measures (GCPS, PHQ-9, GAD-7, PHQ-15, andOHIP- G14), muscle activity, and kinematics were assessed at baseline, 4 weeks, and 8 weeks. Compliance was assessed using asmartphone app, which recorded daily stimulation time and intensity.Results: Recruitment and retention rates were high (100% and 90%, respectively), with 83% adherence to the intervention.Participants receiving taVNS showed a large effect on oral health-related quality of life, and at least a small but potentially impor-tant effect on pain intensity, anxiety, depression, severity of somatic symptoms, muscle activity, and kinematics. However, noneof these differences were statistically significant. No serious adverse events were identified.
001052301 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001052301 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x1
001052301 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001052301 7001_ $$aKaldenhoven, Vanessa$$b1
001052301 7001_ $$aHugger, Alfons$$b2
001052301 7001_ $$0P:(DE-Juel1)131693$$aLangner, Robert$$b3$$ufzj
001052301 7001_ $$aGierthmuehlen, Petra C.$$b4
001052301 7001_ $$aGierthmuehlen, Mortimer$$b5
001052301 773__ $$0PERI:(DE-600)2007587-X$$a10.1111/joor.70039$$gVol. 52, no. 12, p. 2351 - 2360$$n12$$p2351 - 2360$$tJournal of oral rehabilitation$$v52$$x0305-182X$$y2025
001052301 8564_ $$uhttps://juser.fz-juelich.de/record/1052301/files/J%20of%20Oral%20Rehabilitation%20-%202025%20-%20Prott%20-%20Transcutaneous%20Auricular%20Vagus%20Nerve%20Stimulation%20for%20the%20Treatment%20of.pdf$$yOpenAccess
001052301 909CO $$ooai:juser.fz-juelich.de:1052301$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001052301 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131693$$aForschungszentrum Jülich$$b3$$kFZJ
001052301 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001052301 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
001052301 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
001052301 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001052301 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ORAL REHABIL : 2022$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
001052301 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001052301 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
001052301 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-06$$wger
001052301 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
001052301 920__ $$lyes
001052301 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
001052301 980__ $$ajournal
001052301 980__ $$aVDB
001052301 980__ $$aUNRESTRICTED
001052301 980__ $$aI:(DE-Juel1)INM-7-20090406
001052301 9801_ $$aFullTexts